• A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.

  NCT07414316

  RecruitingInterventionalEarly Phase 1Updated Feb 17, 2026
• A Clinical Study GK01 Cell Injection in Subjects With Advanced Lung Cancer

  NCT07673419

  Not yet recruitingInterventionalEarly Phase 1Updated Jun 29, 2026
• A Clinical Study GK01 Injection in Subjects With Advanced Malignant Solid Tumors

  NCT07482319

  Not yet recruitingInterventionalPhase 1Updated Mar 23, 2026
• A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor

  NCT06954558

  RecruitingInterventionalPhase 1Updated May 1, 2025
• A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors

  NCT07351903

  RecruitingInterventionalPhase 1Updated Jan 20, 2026
• A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid Tumors

  NCT07407985

  Active, not recruitingInterventionalPhase 1Updated Feb 12, 2026

ClinicalTrials.gov ID

NCT07412665

Lead Sponsor

Beijing Geekgene Technology Co., LTDINDUSTRY

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Early Phase 1

Enrollment

10Estimated

Last Update Posted

Jun 25, 2026Actual

Start Date

Jun 2026Estimated

Primary Completion Date

Mar 31, 2027Estimated

Completion Date

Mar 31, 2028Estimated

Official Title

A Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of GK01 Cell Injection in Subjects With Advanced Solid Tumors.

Brief Summary

This study is an open-label, single-arm clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of GK01 in patients with advanced solid tumors.

• Advanced Solid Tumors

• GK01 injection

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Ability to understand and sign a written informed consent document.
• At the date of signing ICF, 18 ~70 years old, male or female.
• Histologically or cytologically confirmed advanced solid tumors, progressed on standard treatment, or intolerant to standard treatment, or without standard treatment; locally recurrent disease must be unsuitable for radical surgical resection or radiotherapy.
• At least one measurable lesion that has not been irradiated or received other local therapies.
• At least one measurable lesion remains (RECIST 1.1 criteria).
• ECOG 0-1 points.
• Expected survival time more than 3 months.
• Adequate hematologic and organ function.
• No absolute or relative contraindications to surgery, bronchoscopy, or percutaneous procedures.

Exclusion Criteria:

• History of severe allergy, or hypersensitivity to any component of the drugs used in this study, including but not limited to lymphodepleting chemotherapy drugs, contrast agents for radiological examinations, and excipients of GK01 (such as dimethyl sulfoxide).
• Any investigational drug or systemic anti-tumor therapy within 28 days prior to the start of lymphodepleting chemotherapy preconditioning, or within 5 half-lives of the previous drug.
• Extensive field radiotherapy within 28 days prior to ICF signing, exception of local radiotherapy for symptomatic palliation of non-target lesions.
• Major surgery within 28 days prior to signing the ICF, or planned during the study period.
• Toxicities from previous anti-tumor therapies have not recovered to ≤ Grade 1 or baseline level (according to NCI-CTCAE version 5.0) at the time of signing the ICF, with the exception of alopecia and hyperpigmentation.
• Any uncontrolled active infection requiring parenteral antibiotic, antiviral, or antifungal therapy within 4 weeks prior to signing the ICF or before the first infusion.
• History of or current active autoimmune disease that has the potential to recur (including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis, psoriasis, etc.), or subjects at such risk.
• Prior history of bone marrow or organ transplantation.
• Concurrent or prior history of interstitial lung disease or interstitial pneumonia.
• History of active tuberculosis infection within 1 year prior to screening (subjects with a history of active tuberculosis infection more than 1 year ago may be enrolled if the investigator confirms there is no current evidence of active tuberculosis).
• History of other primary malignancies within 5 years prior to the initiation of the study treatment.
• Clinically significant cardiovascular disease.
• History of bleeding within 6 months prior to signing the ICF.
• Metabolic disorders, such as diabetes mellitus (with glycated hemoglobin [HbA1c] ≥8.5%), or other non-malignant organ or systemic diseases, or secondary reactions to cancer that may lead to high medical risk and/or uncertainty in survival assessment.
• Central nervous system (CNS) metastases, leptomeningeal disease, or metastatic spinal cord compression; or a history of CNS disorders.
• Live/attenuated or inactivated vaccine within 28 days prior to signing the ICF, or planned administration of a live/attenuated or inactivated vaccine during the screening period.
• Systemic corticosteroid therapy (at a dose equivalent to or greater than 10 mg/day of prednisone) or other immunosuppressive medications within 14 days prior to tissue acquisition or during the study period.
• Hepatitis B surface antigen (HBsAg) positivity; With negative HBsAg positive hepatitis B core antibody (HBcAb) ,and if peripheral blood hepatitis B virus (HBV) DNA positive; Hepatitis C virus (HCV) antibody positive and HCV RNA positive; Human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA positive; Both Treponema pallidum-specific and non-specific antibody tests are positive.
• Female subjects who are pregnant or breastfeeding.

Primary Purpose

Treatment

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Beijing Geekgene Technology Co., LTDINDUSTRY

Collaborators

Peking University Cancer Hospital & InstituteOTHER

doctorshenlin@sina.cn+86-010-88196561